

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,670	91.6%	20,525	92.2%	1,973	87.8%	1,909	90.6%	124	92.5%	3,009	87.2%
Epidermoid carcinoma ^d (8051-8131)	202	0.8%	157	0.7%	20	0.9%	22	1.0%	-	-	34	1.0%
Adenocarcinoma ^e	22,644	84.1%	18,937	85.0%	1,713	76.2%	1,765	83.8%	111	82.8%	2,711	78.5%
Adenocarcinoma, NOS (8140)	3,108	11.5%	2,515	11.3%	399	17.8%	169	8.0%	-	-	318	9.2%
Papillary adenocarcinoma, NOS (8050,8260)	357	1.3%	304	1.4%	34	1.5%	-	-	-	-	48	1.4%
Clear cell adenocarcinoma (8310,9110)	1,434	5.3%	1,098	4.9%	60	2.7%	264	12.5%	-	-	161	4.7%
Endometrioid carcinoma (8380-8383,8570)	2,640	9.8%	2,201	9.9%	131	5.8%	277	13.1%	-	-	401	11.6%
Cystadenocarcinoma, NOS (8440,8450)	98	0.4%	80	0.4%	-	-	-	-	-	-	17	0.5%
Serous cystadenocarcinoma (8441)	6,303	23.4%	5,388	24.2%	433	19.3%	409	19.4%	41	30.6%	663	19.2%
Papillary serous cystadenocarcinoma (8460-8462)	5,863	21.8%	5,019	22.5%	452	20.1%	347	16.5%	26	19.4%	712	20.6%
Mucinous cystadenocarcinoma (8470-8473)	389	1.4%	315	1.4%	27	1.2%	43	2.0%	-	-	60	1.7%
Mucinous adenocarcinoma (8480,8482)	984	3.7%	779	3.5%	84	3.7%	107	5.1%	-	-	148	4.3%
Mucin-producing adenocarcinoma(8481)	41	0.2%	33	0.1%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,427	5.3%	1,205	5.4%	77	3.4%	127	6.0%	-	-	179	5.2%
Other specific carcinomas ^g	640	2.4%	454	2.0%	128	5.7%	45	2.1%	-	-	100	2.9%
Stromal cell tumor (8620-8631,8650)	451	1.7%	304	1.4%	105	4.7%	30	1.4%	-	-	70	2.0%
Other ^h	189	0.7%	150	0.7%	23	1.0%	-	-	-	-	30	0.9%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,184	4.4%	977	4.4%	112	5.0%	77	3.7%	-	-	164	4.8%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2008-2012
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	91	0.3%	61	0.3%	20	0.9%	-	-	-	-	20	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,874	7.0%	1,453	6.5%	222	9.9%	167	7.9%	-	-	381	11.0%
Mullerian mixed tumor (8950-8951,8980)	813	3.0%	684	3.1%	74	3.3%	45	2.1%	-	-	80	2.3%
Teratoma, malignant (9080-9085,9102)	415	1.5%	286	1.3%	64	2.8%	55	2.6%	-	-	148	4.3%
Other	646	2.4%	483	2.2%	84	3.7%	67	3.2%	-	-	153	4.4%
Unspecified (8000-8005)	293	1.1%	233	1.0%	32	1.4%	22	1.0%	-	-	42	1.2%
Total ^d	26,928	100.0%	22,272	100.0%	2,247	100.0%	2,107	100.0%	134	100.0%	3,452	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.